报告题目：Mass Spectrometry-based Investigation of Metabolic Adaptations and Reprogramming in Cells and Mice
报 告 人：胡泽平（德克萨斯大学西南医学中心儿童研究所 助理教授）
报告时间：2015年9月29日（星期二）上午9:00
报告地点：独墅湖校区二期云轩楼2301室
报告摘要：
Metabolism is at the root of physiology, and most human diseases involve the perturbation of metabolism. Metabolomics and metabolic flux analysis (MFA) are critial complementary platforms for metabolism study by measuring metabolites and the rates of metabolite turnover and flux through the metabolic pathways. A variety of mass spectrometry-based metabolomics and MFA methods have been developed and used for the metabolism study of physiology and diseases, including stem cells and cancer. 1) Particularly, an ultra-sensitive targeted metabolomics platform was used to measure metabolites in small numbers of hematopoietic stem cells (HSCs). We found HSCs are metabolically distinctive from other bone marrow cells. 2) In a study exploring the reductive carboxylation pathway in the setting of mitochondrial impairment, we found that reductive carboxylation requires bidirectional α-ketoglutarate metabolism along oxidative and reductive pathways, with the oxidative pathway producing reducing equivalents used to operate isocitrate dehydrogenase in reverse. 3) By profiling the metabolome in efficiently metastasizing and inefficiently metastasizing human melanomas, we found that efficiently metastasizing melanomas underwent reversible metabolic changes during metastasis that allowed them to cope with oxidative stress, including increased NADPH production through the folate pathway. In addition, anti-oxidants promoted distant metastasis by human melanomas in NOD scid gamma (NSG) mice, whereas pro-oxidants inhibited distant metastasis.
报告人简介：
Dr. Zeping Hu is a research assistant professor in the Children Research Institute at the University of Texas Southwestern Medical Center. He is also the facility manager and technical director of the Metabolomics Facility at the Children Research Institute. Dr. Hu obtained his Bachelor of Medicine degree in Preventive Medicine from Shandong University, and Master degree in Pharmacology from the National Institutes for Food and Drug Control. After his PhD study in the National University of Singapore, Dr. Hu went to the Pacific Northwest National Laboratory in the US for postdoc training. In 2012, Dr. Hu joined the UT Southwestern Medical Center as a faculty member.
Dr. Hu’s research has been focused on the mass spectrometry-based metabolomics and metabolic flux analysis, and using these tools to elucidate the metabolic mechanisms of diseases, particularly cancer. In addition, his research has been focused on drug-drug interactions, pharmacokinetics, drug metabolism and transport.
